|Bid||19.55 x 1000|
|Ask||28.00 x 900|
|Day's Range||23.55 - 24.25|
|52 Week Range||16.75 - 30.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.00|
Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, President and Chief Executive Officer is scheduled to speak at the William Blair 38th Annual Growth Stock Conference in Chicago, Illinois on Wednesday, June 13, 2018 at 2:40 PM, Central Time. The company recently obtained FDA marketing authorization for antimicrobial susceptibility testing direct from positive blood culture samples using its Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit. The system and kit leverage proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics. The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing.
On a per-share basis, the Tucson, Arizona-based company said it had a loss of 37 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
TUCSON, Ariz., May 09, 2018-- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending March 31, 2018. The company generated revenue of $801,000, up 51% from the prior year, ...
NEW YORK, May 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of US ...
TUCSON, Ariz., April 30, 2018-- Accelerate Diagnostics, Inc. announced today it will host a conference call on Wednesday, May 9, 2018 to review its first quarter 2018 financial results and commercial progress. ...
TUCSON, Ariz., April 21, 2018-- Accelerate Diagnostics, Inc. today announced the sizeable release of new data presented by the company, its customers, and clinical experts during the European Congress ...
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
Accelerate Diagnostics Inc (NASDAQ:AXDX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Insider buying can be an encouraging signal for potential investors. Several health care companies saw notable insider buying this past week. Insiders included a company founder and a renowned former CEO. ...
The Tucson, Arizona-based company said it had a loss of 27 cents per share. The maker of systems that diagnose drug-resistant infections posted revenue of $2.1 million in the period. For the year, the ...
Short interest is moderately high for AXDX with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding AXDX totaled $457 million.
How Is Accelerate Diagnostics Positioned at the Start of 2018? In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock. As a result of the offering, the cash position of the company increased to $121.3 million at the end of 3Q17 as compared with $77.8 million at the end of 3Q16.
How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.
How Is Accelerate Diagnostics Positioned at the Start of 2018? Accelerate Diagnostics’ (AXDX) Pheno System utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests (or AST), which determine if live bacterial or fungal cells are resistant or susceptible to a particular antimicrobial agent. The kit includes 140 assays for identification and susceptibility testing.
Tuscon-based Accelerate Diagnostics (AXDX) is a diagnostics company focused on developing solutions and tools to provide rapid diagnostic results. While results from traditional culture-based tests usually take two to three days, Accelerate’s technology platform is built to deliver substantially faster and more accurate testing of infectious pathogens. The platform is intended to rapidly diagnose infectious pathogens.